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The paper summarizes the history of the development of the guidance on risk assess-
ment, including the roadmap under the Cartagena Protocol on Biosafety since 2008 until 
now. The aim and the contents of the roadmap for risk assessment of living modified 
organisms (LMOs) are described, in particular the five steps in the risk assessment pro-
cess. After several rounds of discussions at the expert and political level, the guidance 
including the roadmap is currently revised taking into account the results of an in-depth 
practical testing process by the Parties, Non-Parties, and relevant organizations. The aim 
is to provide an improved version of the guidance for endorsement and broad support by 
the next meeting of the Parties to the Cartagena Protocol in December 2016.
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BRieF HiSTORY OF THe ROADMAP UnDeR THe CARTAGenA 
PROTOCOL On BiOSAFeTY
The Cartagena Protocol on Biosafety was adopted in January 2000 as a Protocol to the Convention 
on Biological Diversity (Secretariat of the Convention on Biological Diversity, 2000). It entered into 
force on 11 September 2003 after the ratification by 50 Parties. Currently (June 2015), it has been 
ratified by 170 Parties. The objective of the Protocol is to contribute to ensuring an adequate level of 
protection in the field of the safe transfer, handling, and use of living modified organisms (LMOs), 
specifically focusing on the transboundary movements. Due to consistency with the Convention on 
Biological Diversity, the term LMOs is used in the Protocol, according to the definition, this means 
the same as the term genetically modified organisms (GMOs) in other regulatory frameworks.
Risk assessment as the basis of decision making is at the heart of the Protocol, which contains in 
its Annex III further details on the objective, the use, the general principles as well as methodology 
and points to consider for an appropriate risk assessment.
Since the entry into force of the Protocol, Parties have discussed whether and how to complement 
the provisions of the Protocol on risk assessment by further guidance, providing more details to 
practitioners.
For that purpose, the Parties to the Protocol at their fourth meeting in May 2008 in Bonn, 
Germany, established an expert group of about 30 experts1 with the tasks to:
 (a) develop a “Roadmap” on risk assessment of LMOs and
 (b) explore the development of further guidance of risk assessment.
1 Officially this expert group has been called Ad Hoc Technical Expert Group (AHTEG) on Risk Assessment and Risk 
Management under the Cartagena Protocol on Biosafety. For reasons of simplifying the language, it will be called “expert 
group” throughout this article.
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The expert group worked intensively to fulfill its tasks and 
provided recommendations to the various meetings of the 
Parties. The seventh meeting of the Parties in October 2014 in 
Pyeongchang, South Korea, decided a continuation of a so-called 
open-ended online forum,2 a continuation of the work of the 
expert group in an expanded form (six new members) and gave 
both – the online forum and the expert group – a new mandate 
(see chapters below).
COnTenTS OF THe GUiDAnCe On RiSK 
ASSeSSMenT OF LMOs
The draft guidance on risk assessment of LMOs (Biosafety 
Clearing-House, 2012) in its current form consists of the follow-
ing parts: Part 1 is the Roadmap for risk assessment of LMOs. Part 
2 covers the risk assessment of specific types of LMOs and traits, 
with the following subchapters: living modified (LM) plants with 
stacked genes or traits, LM plants with tolerance to abiotic stress, 
LM trees, and LM mosquitoes. Part 3 covers the monitoring of 
LMOs released into the environment. Finally, there is a section 
on the use of terms (definitions).
This paper focuses on part 1 of the Guidance, the development 
of the roadmap for risk assessment of LMOs, in the following.
THe COnTenTS OF THe ROADMAP FOR 
RiSK ASSeSSMenT OF LMOs
The roadmap is not meant to substitute the provisions of the 
Protocol, nor is it meant to be prescriptive or legally binding. 
It rather builds on and supplements Annex III of the Cartagena 
Protocol. It elaborates on how to undertake an LMO risk assess-
ment, in particular by outlining the different steps in the risk 
assessment, suggesting several points to consider for each step 
and providing links to various sources of background material 
(peer reviewed literature, studies, and other publications by 
various institutions etc.). It is meant as a reference document 
for LMO risk assessors, those who conduct and/or review a risk 
assessment and it can serve as a training tool in capacity building.
It covers in principle all types of LMOs and all types of appli-
cations (field trials, placing on the market of commercial LMO 
products).
The main chapters are the following:
The chapter on “Overarching issues in the risk assessment pro-
cess” describes which criteria the quality of scientific information 
should meet. It also describes which information including data 
may be considered relevant for the risk assessment. It outlines 
how uncertainty should be identified and considered throughout 
the risk assessment process.
The chapter on “Planning phase of the risk assessment” is 
crucial as it describes that the risk assessment should be embed-
ded in a context, such as the existing policies, guidelines, and 
regulatory frameworks on biosafety in the respective country or 
2 The open-ended online forum has been established to complement the work by 
the expert group. It consists of a few hundred experts on biosafety around the 
world, nominated by the focal points of the Parties to the Protocol and observers. 
They work electronically and in a structured form to provide their expert input.
region. Identification or clarification of protection goals, assess-
ment endpoints, risk thresholds, and management strategies are 
important starting points for the risk assessment. In addition, 
this chapter refers to the process and criteria for the choice of 
the appropriate comparators and the challenges attached to that.
The chapter on “Conducting the risk assessment,” includ-
ing the five steps is at the heart of the roadmap and is further 
described in the chapter below.
Figure 1 below refers to a Flowchart as a visualization of the 
roadmap.
THe Five STePS OF THe RiSK 
ASSeSSMenT PROCeSS
The roadmap in its core chapter outlines the following five steps 
in the risk assessment process:
Step 1: identification of the potential adverse effects of the 
LMO resulting from its genetic modification (“hazard 
identification”).
Step 2: evaluation of the likelihood of the adverse effect being 
realized.
Step 3: evaluation of the consequences should the adverse effect 
be realized.
Step 4: on the basis of Steps 1–3, the estimation of the risk, includ-
ing the overall risk when all potential adverse effects, their 
likelihood and consequence are taken into account.
Step 5: recommendation on whether the risk is acceptable or 
manageable and any risk management strategies.
For each of the five steps, the roadmap establishes the rationale 
for the considerations in the respective step, any points to con-
sider as well as provides links to relevant background material 
from various sources.
In Step 1, when identifying potential adverse effects, the 
rationale for the step is for example that the risk assessor needs 
to identify changes in the LMO that could cause adverse effects, 
be it direct or indirect, immediate or delayed. It is also relevant 
if there is a causal link or pathway between the characteristics 
of the LMO and the potential adverse affect. Points to consider 
can be for example if there are potential adverse effects on non-
target organisms, such as toxicity, allergenicity, any multi-trophic 
effects, that can affect the survival, development or behavior of 
these organisms. These points to consider can often be backed 
up by relevant background material, such as scientific literature.
THe CURRenT STAGe OF THe ROADMAP 
FOR RiSK ASSeSSMenT OF LMOs
The latest version of the current draft roadmap dates back to July 
2012. The progress on this “living document,” which is neither 
meant to be prescriptive nor to impose any obligations on Parties 
was commended by the sixth Meeting of the Parties to the Protocol 
in October 2012 in Hyderabad, India. It had also encouraged to 
use the Guidance, including the roadmap in implementing the 
provisions on unintentional transboundary movement (Article 
17 of the Cartagena Protocol). It also suggested that testing of the 
FiGURe 1 | Flowchart of the roadmap: (taken from Biosafety Clearing-House, 2012).
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draft Guidance should take place. Subsequent to the testing differ-
ent kinds of feedback was provided by the Parties and observers. 
Some showed strong support to the document in its current form, 
others suggested further revision and improvement.
The seventh meeting of the Parties to the Protocol in October 
2014 adopted a decision in which it welcomed the results of the 
testing, invited the Parties and observers to further test or use the 
draft guidance, including its use as a capacity-building tool. It also 
suggested a concrete mechanism for revision and improvement 
of the draft guidance. The links to the background material are 
constantly being reviewed and updated, as well.
ReFLeCTiOnS On THe wAY FORwARD
The development of the draft roadmap has been and continues to 
be a challenging multi-stakeholder consultative process led by the 
Parties. This has resulted in a steady and stepwise progress in the 
development of the document. The recent meeting of the Parties 
decided on a “two-track” approach, which is a good basis for further 
progress: on the one hand, the results of the testing will lead to a 
revision and improvement. On the other hand, there is an ongoing 
invitation to further test and use the Guidance, also for capacity-
building activities. All in all, a practical and efficient mechanism 
for revision and improvement of the guidance is needed and is 
currently developed and implemented by the online forum and 
the expert group. The aim is to provide an improved version of the 
guidance, including the roadmap, for endorsement and broad sup-
port at the next meeting of the Parties in December 2016 in Mexico.
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